Electroacupuncture on Menstrual Frequency in Women With Polycystic Ovary Syndrome: Study Protocol

Launched by GUANG'ANMEN HOSPITAL OF CHINA ACADEMY OF CHINESE MEDICAL SCIENCES · Jan 10, 2016

Keywords

ClinConnect Summary

Methods: A total of 172 participants diagnosed with polycystic ovary syndrome would be randomly assigned to either the acupuncture group or sham-acupuncture group, at a ratio of 1:1. Participants in both groups will receive treatment for 12 weeks, three times a week. The primary outcome will be the proportion of participants with at least a 50% increase from baseline in the monthly menstrual frequency from baseline after 12 weeks intervention, while secondary outcomes will be the difference in anthropometrics, serum hormone level, ovarian morphology, anxiety and depression, and quality of l...

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Participants fulfilling any one of the following criteria will be excluded. Participants who fulfill the following criteria will be included.
• • Participants meet the Rotterdam diagnostic criteria with oligomenorrhea or amenorrhea. (Oligomenorrhoea is defined as an intermenstrual interval of \>35 days or \<8 menstrual bleedings in the past year. Amenorrhoea is defined as absent menstrual bleeding or no menstrual bleeding in the previous 90 days.)
• * Participants who have at least two of the following features that meet the Rotterdam diagnostic criteria:
• • 1. Clinical or biochemical hyperandrogenism: Biochemical hyperandrogenaemia is defined as a total serum testosterone concentration above normal threshold, and/or clinical hyperandrogenism is defined as a Ferriman-Gallwey (FG) score of ≥5 or acne defined by the Global Acne Grading System (GAGS) as "mild"/ "moderate"/ "severe"/ "very severe".
• • 2. Polycystic ovary morphology is defined as the presence of ≥12 follicles in each ovary measuring 2-9 mm in diameter and/or an ovarian volume \>10 mL on transvaginal ultrasound.
• • Participants who are between 18 to 40 years old.
• • Participants who joined the research and provided a signed informed consent voluntarily.
• Exclusion Criteria:
• • Participants with fertility requirements.
• • Participants with oligomenorrhea or amenorrhea caused by hyperandrogenemia, premature ovarian failure, or hypothalamus or pituitary disorders.
• • Participants with hyperandrogenism caused by congenital adrenal hyperplasia, Cushing's syndrome and androgen-secreting tumors.
• • Participants with endocrine disorders such as thyroid dysfunction, adrenal disorders, hyperprolactinemia and diabetes mellitus.
• • Participants with severe heart disease, hepatic disease, renal system and hematopoietic system disease, or malnutrition of the whole body.
• • Participants who use hormones or other medications that would affect reproductive function, or received the same protocol of this study in the past three months.